

NACLC Disclosure List

Name	Ineligible Company	Type of Relationship	Role in Activity
Aadel Chaudhuri	- Guardant Health (ended 12/2024), Exact Sciences (ended 8/2025), Caris (ended 8/2024), Geneoscopy (active), Illumina (active), NeoGenomics (ended 11/2025), ThermoFisher (ended 11/2025) - Droplet Biosciences (Co-Founder; active), LiquidCell Dx (Co-Founder, Board Member; active), CytoTrace Biosciences (Co-Founder, Board Member; active)	- Advisor - Owner	Speaker
Adam Schoenfield	- GSK (Inst), Obsidian (Inst), Lilly (Inst), AstraZeneca (Inst), BioNTech (Inst), Clasp Therapeutics (Inst), PACT pharma (Inst), Iovance Biotherapeutics (Inst), Achilles therapeutics (Inst), Merck (Inst), SyntheKine (Inst), BMS (Inst), Harpoon Therapeutics (Inst), AffiniT therapeutics (Inst), Legend Therapeutics (Inst), SyntheKine (Inst) and Amgen (Inst). - J&J, Bayer, KSQ therapeutics, BioNTech, BMS, Merck, AstraZeneca, Oxford Biotherapeutics, Roche, SyntheKine, CTRL therapeutics, Regeneron, Enara Bio, Perceptive Advisors, Foresight Diagnostics, Oppenheimer	- Research (Funding Paid to Institution) - Advisor	Speaker

	and Co, Umoja Biopharma, Legend Biotech, Iovance Biotherapeutics, Obsidian Therapeutics, Prelude Therapeutics, Immunocore, Lyell Immunopharma, Amgen, Boehringer Ingelheim and Heat Biologics.		
Aditya Juloori	1. AstraZeneca, Merck, Regeneron, EMD Serono, Nanobiotix, DSI	1. Consultant	Speaker
Amy Cummings	1. Amgen, AstraZeneca, Novartis, Roche/Genentech, Tempus 2. AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Genmab, Johnson & Johnson, Merus, MJH Life Sciences, OncoHost, Pfizer Roche/Genentech, Tempus 3. Schmid & Voiles	1. Research (Funding Paid to Institution) 2. Consultant 3. Independent Contractor	Speaker
Ana Valeazquez-Manana	1. Janssen, Genentech/Roche 2. AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, DSI, Janssen, Regeneron, Novocure, Nuvation Bio, Cadence Communications & Research, Medscape, MJH LifeSciences, BioAscend, Curio Science	1. Research (Funding Paid to Institution) 2. Consultant	Session Chair
Bruna Pellini	1. Bristol Myers Squibb Foundation, Merck/MSD 2. Bristol Myers Squibb, Bayer, Guidepoint, Foundation Medicine, Gilead 3. Oncohost, Catalyst, Merus, AstraZeneca, Regeneron, Illumina, Guardant Health, Bristol Myers Squibb	1. Research (Funding Paid to Institution) 2. Consultant 3. Advisor	Speaker

Christine Bestvina	1. AstraZeneca, BMS 2. AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CVS, Daiichi Sankyo, EMD Serono, Genentech, Gilead, Guardant, Jazz, Johnson & Johnson, Mirati, Novartis, Pfizer, Tempus, Turning Point Therapeutics	1. Research (Funding Paid to Institution) 2. Consultant	Session Chair
Daniel Gomez	1. Varian, Johnson & Johnson, AstraZeneca, Summit, Amgen, Personalis 2. Regeneron, AstraZeneca, Johnson & Johnson	1. Research (Funding Paid to Institution) 2. Consultant	Speaker
Deborah Doroshov	1. Boehringer Ingelheim, Takeda, AstraZeneca, Summit Therapeutics	1. Consultant	Speaker
Dwight Owen	1. BMS, Merck, Palobiofarma, Genentech, Onc.AI, Pfizer 2. Chugai	1. Research (Funding Paid to Institution) 2. Consultant	Speaker
Erin Gillaspie	1. Intuitive Surgical 2. Astra Zeneca, Genentech, Daiichi Sankyo, OncLive, BMS	1. Consultant 2. Advisor	Conference Chair/Session Chair
Frank Weinberg	1. AstraZeneca, Lily 2. Jazz, Tempus, Regeneron 3. AstraZeneca, Lily, Boehringer-Ingelheim, Regeneron, Tempus	1. Research (PI) 2. Consultant 3. Advisor	Speaker
Gavitt Woodward	1. AstraZeneca, BMS	1. Consultant	Speaker
Greg Durm	1. Astra Zeneca, Merck, Bristol Myers Squibb	1. Research (Funding Paid to Institution)	Speaker
Helen Ross	1. GSK, AstraZeneca, Johnson & Johnson	1. Advisor	Session Chair/Speaker
Ibiayi Dagogo-Jack	1. AstraZeneca, Bayer, BostonGene, Bristol Myers Squibb, Catalyst, Eli Lilly, Genentech, Janssen, Merus, Novocure, Nuvalent, Pfizer,	1. Consultant 2. Research (Funding Paid to Institution)	Speaker

	Vivace, Sanofi/Genzyme, ThermoFisher Scientific 2. Array, BostonGene, Genentech, Novartis, Pfizer		
Jay Lee	1. AstraZeneca, Bristol Myers Squibb, Genentech, Merck, Novartis, Roche, Tempus 2. Boehringer Ingelheim, Genentech, Lilly, Merck, Novartis, Roche 3. AstraZeneca, AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Foundation Medicine Institute, Genentech, Lilly, Merck, Novartis, Regeneron Pharmaceuticals, Roche 4. AstraZeneca, AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Foundation Medicine Institute, Genentech, Lilly, Merck, Novartis, Regeneron Pharmaceuticals, Roche	1. Research (Funding Paid to Institution) 2. Steering Committee 3. Consultant 4. Advisor	Speaker
Javier Torres-Roca	1. Cvergenx, Inc	1. Owner	Speaker
Jia Luo	1. Amgen, Black Diamond Therapeutics, Genentech, Kronos Bio, Novartis, Revolution Medicines 2. Amgen, AstraZeneca	1. Research (Funding Paid to Institution) 2. Consultant	Speaker
Jing Zeng	1. IBA 2. IBA, AstraZeneca	1. Research (Funding Paid to Institution) 2. Consultant	Speaker
Joseph Murray	1. Johnson and Johnson 2. AstraZeneca 3. Caris	1. Research (PI) 2. Consultant 3. Advisor	Speaker
Joseph Shrager	1. Becton Dickinson, Inc. 2. Lungpacer, Inc.	1. Consultant 2. Advisor	Session Chair/Speaker
Julie Brahmer	1. AstraZeneca, Merck 2. Mestag 2024, Summit Therapeutics 2024,	1. Research (Funding Paid to Institution)	Session Chair

	AstraZeneca, Amgen, Bayer, Bristol Myers Squibb, GlaxoSmithKline, Foundation Medicine, Johnson & Johnson, Genmab (DSMB),	2. Advisor	
Kathryn Arbour	1. Revolution Medicines, Lilly, Verastem, Mirati, Bristol Myers Squibb, Treeline Therapeutics 2. Revolution Medicines, Lilly, Bristol Myers Squibb, Nuvalent, G1 Therapeutics, Regeneron, Merck	1. Research (Funding Paid to Institution) 2. Advisor	Speaker
Koosha Paydary	1. American Journal of Managed Care, Partner Therapeutics, Catalyst Pharmaceuticals	1. Advisor	Speaker
Kristen Marrone	1. BMS, Lilly, Revolution Medicines, Amgen 2. AstraZeneca, Bristol-Myers Squibb, Lilly, Regeneron, Merus, Revolution Medicines, Mirati	1. Research (Funding Paid to Institution) 2. Consultant	Conference Chair/Session Chair
Mara Antonoff	1. astra zeneca, bristol myers squibb, johnson and johnson, merck	1. Consultant	Speaker
Marina Garassino	1. AstraZeneca, Merck, Bayer, Nuvalent, Regeneron	1. Advisor	Speaker
Mohamed Abazeed	1. Varian Medical Systems, Inc.	1. Research (Funding Paid to Institution)	Speaker
Nathaniel Myall	1. Genentech	1. Research (PI)	Speaker
Noura Choudhury	1. Janux, Seagen/Pfizer, Merck, AbbVie, Amgen, Monte Rosa Therapeutics, Roche/Genetech 2. MJH Life Sciences, IDEOlogy Health 3. Merck, AbbVie, Harpoon Therapeutics, Eli Lilly 4. Wolters Kluwer	1. Research (Funding Paid to Institution) 2. Consultant 3. Advisor 4. Royalties	Speaker

Patrick Forde	1. AstraZeneca, BMS, Roche, Summit, BioNTech, Regeneron 2. Ascendis, AstraZeneca, BioNTech, BMS, Curevac, Novartis, Novocure, Regeneron, G1, Genelux, Genentech, Gritstone, Janssen, F Star, Sanofi, Amgen, Fosun, Teva, Summit, SyntheKine, Flame, Iteos, Tavotek, Teva	1. Research (Funding Paid to Institution) 2. Consultant	Speaker
Ramesh Rengan	1. Ion Beam Applications 2. Lila Biologics	1. Speaker Bureau 2. Advisor	Conference Chair/Session Chair
Saamil Gandhi	1. Bristol Myers Squibb, Takeda, Nanobiotix, Johnson & Johnson 2. Johnson & Johnson 3. NCCN, Gateway Foundation	1. Research (Funding Paid to Institution) 2. Advisor 3. Grant	Speaker
Vincent Lam	1. Bristol Myers Squibb, Iovance Biotherapeutics, Pfizer, Genentech/Roche, Lilly, Nuvation Bio, and Guardant Health	1. Consultant	Session Chair/Speaker

“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”

These financial relationships with ineligible companies have been mitigated by the International Association for the Study of Lung Cancer.

All other presenters, planners, editors, or staff report no relationships to disclose:

“I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”